Membrane biology

Biocomposites presents STIMULAN® data at the MSIS 31st Annual Open Scientific Meeting 2021

Retrieved on: 
Wednesday, August 4, 2021
Branches of biology, Bacteriology, Biology, Biological matter, Environmental microbiology, Environmental soil science, Membrane biology, Biofilm, Antimicrobial

The company will be sharing research findings relating to the antimicrobial effectiveness of STIMULAN mixed with antibiotics against multispecies biofilm.

Key Points: 
  • The company will be sharing research findings relating to the antimicrobial effectiveness of STIMULAN mixed with antibiotics against multispecies biofilm.
  • It also showed that STIMULAN bead distribution plays an important role in biofilm eradication and reduction of challenging resistant variant colonies.
  • Details of the posters are listed below with links to the 31st Annual Open Scientific Meeting website.
  • Biocomposites products are now used in over 120,000 procedures per annum and sold in more than 40 countries around the world.

Biocomposites presents STIMULAN® data at the MSIS 31st Annual Open Scientific Meeting 2021

Retrieved on: 
Wednesday, August 4, 2021
Branches of biology, Bacteriology, Biology, Biological matter, Environmental microbiology, Environmental soil science, Membrane biology, Biofilm, Antimicrobial

KEELE, England, Aug. 4, 2021 /PRNewswire/ -- Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, today announces the acceptance of two posters at the Musculoskeletal Infection Society's 31st Annual Open Scientific Meeting, which is being held in Fort Lauderdale 6-7 August 2021. The company will be sharing research findings relating to the antimicrobial effectiveness of STIMULAN mixed with antibiotics against multispecies biofilm.

Key Points: 
  • The company will be sharing research findings relating to the antimicrobial effectiveness of STIMULAN mixed with antibiotics against multispecies biofilm.
  • It also showed that STIMULAN bead distribution plays an important role in biofilm eradication and reduction of challenging resistant variant colonies.
  • Details of the posters are listed below with links to the 31st Annual Open Scientific Meeting website.
  • Biocomposites products are now used in over 120,000 procedures per annum and sold in more than 40 countries around the world.

Pacira Announces FDA Approval of Enhanced EXPAREL Manufacturing Process

Retrieved on: 
Monday, August 2, 2021
Branches of biology, Membrane biology, Local anesthetics, Drugs, Pharmacology, Acetanilides, Bupivacaine, Piperidines, Liposome, Approved Drug Products with Therapeutic Equivalence Evaluations, Vesicle

PARSIPPANY, N.J., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced the U.S. Food and Drug Administration (FDA) has approved the company’s enhanced manufacturing process for EXPAREL® (bupivacaine liposome injectable suspension) which is housed at a custom facility in Swindon, England under a partnership with Thermo Fisher Scientific Pharma Services. The company expects to start selling commercial product manufactured in this 200-liter suite later this year.

Key Points: 
  • This FDA approval underscores the quality assurance of our enhanced manufacturing process, which is essential as we scale the production of EXPAREL, said Dave Stack, chairman and chief executive officer of Pacira BioSciences.
  • The patent, Manufacturing of Bupivacaine Multivesicular Liposomes, claims composition of EXPAREL prepared by the improved manufacturing process and has an expiration date of January 22, 2041.Pacira submitted this patent for listing in the FDAs Approved Drug Products with Therapeutic Equivalence Evaluations (the Orange Book) in July 2021.
  • The companys long-acting local analgesic, EXPAREL (bupivacaine liposome injectable suspension) was commercially launched in the United States in April 2012.
  • EXPAREL represents the first and only multivesicular liposome local anesthetic that can be utilized in the peri- or postsurgical setting.

Keystone Bio Advances a More Complete Explanation of Porphyromonas Gingivalis Toxic Virulence Factors as Major Driver of Sporadic Alzheimer’s and Chronic Inflammation

Retrieved on: 
Thursday, July 29, 2021
Biotechnology, Health, Consumer, Other Health, Pharmaceutical, Other Science, Mental health, Research, Managed care, General Health, Hospitals, Science, Dental, Seniors, Branches of biology, Medical specialties, Microbiology, Membrane biology, Bacterial vaginosis, Bacteroidetes, Porphyromonas gingivalis, Reproductive system, Sexual health, Biofilm, Virulence, Vesicle

View the full release here: https://www.businesswire.com/news/home/20210729006009/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210729006009/en/
    Using KB proprietary methods, KB has identified and eliminates a primary driver of our most deadly diseases, Porphyromonas gingivalis and all of its unique virulence factors.
  • A larger HagA Domain virulence factor is found in many AD and some aged matched control brain tissues.
  • Porphyromonas gingivalis Outer Membrane Vesicles as the major drivers of and source for the toxic insult and iron accumulation/deposition in Alzheimers Disease.
  • Porphyromonas gingivalis (Pg) is a primary oral pathogen in the widespread biofilm-induced chronic multi-systems inflammatory disease(s) including Alzheimers disease (AD).

Kane Biotech Announces Cancellation of Options and Issuance of Restricted Share Units

Retrieved on: 
Wednesday, July 21, 2021
Branches of biology, Bacteriology, Biofilm, Biological matter, Environmental microbiology, Environmental soil science, Membrane biology, Biology

WINNIPEG, Manitoba, July 21, 2021 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF), (the Company or Kane Biotech), today announces that it has cancelled 8,470,555 stock options of the Company (the Cancelled Options) of various directors, officers, employees and consultants of the Company.

Key Points: 
  • WINNIPEG, Manitoba, July 21, 2021 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF), (the Company or Kane Biotech), today announces that it has cancelled 8,470,555 stock options of the Company (the Cancelled Options) of various directors, officers, employees and consultants of the Company.
  • The Company also wishes to announce the issuance of 10,739,488 restricted share units of the Company (RSUs) to various directors, officers, employees and consultants of the Company pursuant to the performance and restricted share unit plan of the Company dated April 21, 2021.
  • Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms.
  • StrixNB, DispersinB, Aledex, bluestem, bluestem, silkstem, goldstem, coactiv+, coactive+, DermaKB and DermaKB Biofilm are trademarks of Kane Biotech Inc.

Plus Therapeutics to Announce Second Quarter 2021 Financial Results and Host Conference Call on July 22, 2021

Retrieved on: 
Thursday, July 15, 2021
Liposome, Membrane biology, Pharmacology, Health sciences, Branches of biology

The webcast will be available on the Companys website for 90 days following the live call.

Key Points: 
  • The webcast will be available on the Companys website for 90 days following the live call.
  • Plus Therapeutics is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionuclides for several cancer targets.
  • Central to the Companys drug development is a unique nanotechnology platform designed to reformulate, deliver and commercialize multiple drugs targeting rare cancers and other diseases.
  • This press release contains statements that may be deemed forward-looking statements within the meaning of U.S. securities laws.

ZyVersa Therapeutics' CEO, Stephen C. Glover to Present at 2nd Annual LifeSci Partners' Virtual Private Company Summer Symposium July 21-23, 2021

Retrieved on: 
Thursday, July 15, 2021
Life sciences, Pharmaceutical industry, Natural sciences, Health sciences, Antibiotics, Efflux, Membrane biology, Biopharmaceutical, Medication

WESTON, Fla., July 15, 2021 /PRNewswire/ --ZyVersa Therapeutics, Inc. (ZyVersa), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, is pleased to announce that Stephen C. Glover, ZyVersa's Co-Founder, Chief Executive Officer, and Chairman, is an invited speaker at the 2nd Annual LifeSci Partners' Virtual Private Company Summer Symposium.

Key Points: 
  • WESTON, Fla., July 15, 2021 /PRNewswire/ --ZyVersa Therapeutics, Inc. (ZyVersa), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, is pleased to announce that Stephen C. Glover, ZyVersa's Co-Founder, Chief Executive Officer, and Chairman, is an invited speaker at the 2nd Annual LifeSci Partners' Virtual Private Company Summer Symposium.
  • Mr. Glover's presentation will highlight progress in advancing development of inflammasome inhibitor, IC 100, and cholesterol efflux mediator, VAR 200.
  • For information about ZyVersa's inflammasome inhibitor and cholesterol efflux mediator, visit www.ZyVersa.com .
  • ZyVersa is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop first-in-class drugs.

Kanazawa University research: Regulators for extracellular vesicle production

Retrieved on: 
Tuesday, July 13, 2021
Branches of biology, Biology, Cell biology, Organelles, Vesicles, Membrane biology, Vesicle, Extracellular vesicle, Secretion

KANAZAWA, Japan, July 13, 2021 /PRNewswire/ -- Researchers at Kanazawa University describe in Scientific Reports the identification of small compounds that can regulate the cellular production of extracellular vesicles nanocontainers transporting biomolecules between cells.

Key Points: 
  • KANAZAWA, Japan, July 13, 2021 /PRNewswire/ -- Researchers at Kanazawa University describe in Scientific Reports the identification of small compounds that can regulate the cellular production of extracellular vesicles nanocontainers transporting biomolecules between cells.
  • For the development of therapies, regulators that can inhibit the secretion of specific EVs, without severe side effects, are therefore needed.
  • By screening a large set of biomolecular compounds, Rikinari Hanayama from Kanazawa University and colleagues have now identified 4 potential regulators (1 inhibitor and 3 activators) for EV secretion for a variety of cells.
  • Rikinari Hanayama from Kanazawa University and colleagues have now screened more than 1500 biochemical compounds for their use as regulators of EV secretion either inhibiting or activating the process.

Kanazawa University research: Regulators for extracellular vesicle production

Retrieved on: 
Tuesday, July 13, 2021
Branches of biology, Biology, Cell biology, Organelles, Vesicles, Membrane biology, Vesicle, Extracellular vesicle, Secretion

KANAZAWA, Japan, July 13, 2021 /PRNewswire/ -- Researchers at Kanazawa University describe in Scientific Reports the identification of small compounds that can regulate the cellular production of extracellular vesicles nanocontainers transporting biomolecules between cells.

Key Points: 
  • KANAZAWA, Japan, July 13, 2021 /PRNewswire/ -- Researchers at Kanazawa University describe in Scientific Reports the identification of small compounds that can regulate the cellular production of extracellular vesicles nanocontainers transporting biomolecules between cells.
  • For the development of therapies, regulators that can inhibit the secretion of specific EVs, without severe side effects, are therefore needed.
  • By screening a large set of biomolecular compounds, Rikinari Hanayama from Kanazawa University and colleagues have now identified 4 potential regulators (1 inhibitor and 3 activators) for EV secretion for a variety of cells.
  • Rikinari Hanayama from Kanazawa University and colleagues have now screened more than 1500 biochemical compounds for their use as regulators of EV secretion either inhibiting or activating the process.

With Wellness More Important than Ever, Vasayo Expands the Power of Nutritional Supplements with Advanced Delivery Technology

Retrieved on: 
Monday, July 12, 2021
Other Consumer, Health, Consumer, Fitness & Nutrition, General Health, Biotechnology, Liposome, Membrane biology

Vasayos liposomal technology is an all-natural process that allows the liposome bubble to fully encapsulate an active vitamin or plant-based nutrient.

Key Points: 
  • Vasayos liposomal technology is an all-natural process that allows the liposome bubble to fully encapsulate an active vitamin or plant-based nutrient.
  • For more information on the science and use of this technology in Vasayo products, readers can visit Vasayo.com .
  • For passionate people who seek abundance in life, Vasayo creates products that promote wellness, enhance beauty, and support daily renewal.
  • Through the companys science, Vasayo maximizes the delivery of nutrients to the human body using liposomal technology and other advanced delivery systems.